Guidelines for the management of alopecia areata

Hull, S.P. MacDonald; Wood, M.L.; Hutchinson, P.E.; Sladden, Michael J; Messenger, A.G.

doi:10.1046/j.1365-2133.2003.05535.x

Cited by 186 publications

(108 citation statements)

References 61 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…The annual incidence rate is 20.2 per 100,000 and the lifetime risk is estimated at 1.7% [1]. Although most small AA lesions resolve spontaneously, 14–25% of AA patients referred to secondary and tertiary centers progress to total loss of scalp hair or to loss of all scalp and body hair, from which full recovery is unusual [2, 3]. …”

Section: Introductionmentioning

confidence: 99%

Pulse Corticosteroid Therapy for Alopecia Areata: Study of 139 Patients

Nakajima

Inui

Itami³

2007

Dermatology

View full text Add to dashboard Cite

Background/Aim: Recent reports of pulse corticosteroid therapy for alopecia areata (AA) show its efficacy for patients with a history of ≤1 year but not for recalcitrant cases or alopecia totalis/universalis. The purpose of this study was to evaluate the efficacy and safety of pulse corticosteroid therapy for recent-onset AA patients. Method: A total of 139 severe AA patients aged >15 years were included in this study. The duration from the onset of active hair loss was within 12 months for 125 (89.9%) of those patients. Results: Of the patients, 72.7% had hair loss on >50% of their scalp area. Among the recent-onset group (duration of AA ≤6 months), 59.4% were good responders (>75% regrowth of alopecia lesions), while 15.8% with >6 months duration showed a good response. Recent-onset AA patients with less severe disease (≤50% hair loss) responded at a rate of 88.0%, but only 21.4% of recent-onset patients with 100% hair loss responded. No serious adverse effects were observed.

show abstract

Section: Introductionmentioning

confidence: 99%

Pulse Corticosteroid Therapy for Alopecia Areata: Study of 139 Patients

Nakajima

Inui

Itami³

2007

Dermatology

View full text Add to dashboard Cite

show abstract

“…There is no good evidence suggesting that drugs can cause remission or that therapy alters the ultimate course of the disease. At the present time, topical, intralesional, and systemic steroids, topical and systemic immunotherapy, anthralin, minoxidil, and photochemotherapy are available for the treatment of AA [1,2,3,4]. All treatment plans for patients depend on two major factors: the extent of scalp involvement and the age of the patient.…”

Section: Introductionmentioning

confidence: 99%

“…In contrast, systemic therapy using PUVA, corticosteroids, and cyclosporine has been demonstrated to be impractical [1, 3]. There have been several uncontrolled studies of PUVA treatment for AA, using all types of PUVA (oral or topical psoralen, local or whole body UVA irradiation [15,16,17]), claiming success rates of up to 60–65%.…”

Section: Introductionmentioning

confidence: 99%

“…As with systemic cyclosporine, in general the use of systemic corticosteroid treatment is also limited because of the side effect profile, high relapse rate after a reduction of the dose, and the fact that steroids may be necessary for long periods of time and do not change the ultimate prognosis [1, 3]. In contrast to systemic cyclosporine treatment, however, when we consider the dose, the differences between steroid compounds, administration route, and the duration of treatment, we can plan a virtually infinite number of modalities for systemic corticosteroid treatment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Comparison of the Efficacy, Relapse Rate and Side Effects among Three Modalities of Systemic Corticosteroid Therapy for Alopecia Areata

et al. 2006

View full text Add to dashboard Cite

Background: Systemic corticosteroids are one of the most commonly used therapeutic modalities for patients with extensive alopecia areata (AA), although they entail several drawbacks. Objective: To determine the best modality for systemic corticosteroid use in terms of their efficacy, relapse rate, and side effects. Methods: Fifty-one patients with single or multiple AA (AA/multiplex) and 38 patients with alopecia totalis or AA universalis (AA totalis/universalis) were enrolled in this open study. They were randomly divided into three groups depending on the time of their initial visit. They were administered (1) oral dexamethasone (Dex) 0.5 mg/day for 6 months (Dex group), (2) intramuscular triamcinolone acetonide (imTA) 40 mg once a month for 6 months followed by 40 mg once every 1.5 months for 1 year (imTA group), and (3) pulse therapy (PT) using oral predonine 80 mg for 3 consecutive days once every 3 months (PT group). After the treatment, each treatment modality was evaluated by the response rate, relapse rate, and side effect profile. Results: The response rate of AA/multiplex was significantly better in the imTA group than in the Dex group. The overall relapse rate and that of AA totalis/universalis were significantly better in the PT group than in the Dex group. Dysmenorrhea was the most common and problematic side effect. Impairment of the adrenocortical reserve was seen in 7% of the PT group and 23% of the imTA group, which was recov ered without any further medical treatment. Conclusion: imTA or pulse therapy is effective for AA and has an acceptable level of side effects. The development of a new strategy to reduce the relapse rate is needed.

show abstract

“…Autoimmunity, mainly T-cellmediated is considered to play a main role in the pathogenesis of the disease [1]. AA may affect people of any age and any sex [1], [2].…”

Section: Introductionmentioning

confidence: 99%

Alopecia Areata and Dry Eye

2017

IJSR

View full text Add to dashboard Cite

Guidelines for the management of alopecia areata

Cited by 186 publications

References 61 publications

Pulse Corticosteroid Therapy for Alopecia Areata: Study of 139 Patients

Pulse Corticosteroid Therapy for Alopecia Areata: Study of 139 Patients

A Comparison of the Efficacy, Relapse Rate and Side Effects among Three Modalities of Systemic Corticosteroid Therapy for Alopecia Areata

Alopecia Areata and Dry Eye

Contact Info

Product

Resources

About